相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Myelodysplastic Syndromes, Version 3.2022 Featured Updates to the NCCN Guidelines
Peter L. Greenberg et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes
Louise de Swart et al.
HAEMATOLOGICA (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Luca Malcovati et al.
BLOOD (2020)
Targeting Aberrant Splicing in Myelodysplastic Syndromes Biologic Rationale and Clinical Opportunity
Andrew M. Brunner et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
M. D. Cappellini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Myelodysplastic Syndromes
Mario Cazzola
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia
Antonio Piga et al.
BLOOD (2019)
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux et al.
LEUKEMIA (2018)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
Olivier Kosmider et al.
HAEMATOLOGICA (2016)
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
Olivier Kosmider et al.
HAEMATOLOGICA (2016)
How we treat lower-risk myelodysplastic syndromes
Pierre Fenaux et al.
BLOOD (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L. Greenberg et al.
BLOOD (2009)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
分享论文
